Boom in number of UK cell and gene therapy clinical trials
Year-on-year, the number of trials for advanced therapeutics has doubled, meaning that the UK now represents 12% of all global clinical trials in the area.
Year-on-year, the number of trials for advanced therapeutics has doubled, meaning that the UK now represents 12% of all global clinical trials in the area.
The South Korean company plans to invest ₩600bn over a five-year period to support the construction of its first facility in China.
Health New England switched 93% of infliximab use to biosimilars after adopting a new policy.